Literature DB >> 12845349

How can the current strategies for Helicobacter pylori eradication therapy be improved?

Alex Ford1, Paul Moayyedi.   

Abstract

BACKGROUND: The use of Helicobacter pylori eradication therapy is advocated in an increasing variety of situations. It is therefore important to optimise current strategies to eradicate H pylori infection.
OBJECTIVES: To define the optimum dosage, drugs and duration of proton pump inhibitor (PPI) triple therapy.
METHODS: A review of the literature was performed to identify randomized controlled trials and systematic reviews addressing these issues.
RESULTS: In PPI, amoxicillin and clarithromycin (PAC) based regimens, twice daily PPI gave optimal eradication rates (relative risk reduction [RRR] compared with once daily = 7%; 95% CI 2% to 12%), but in PPI, clarithromycin and metronidazole (PCM) based regimens there was no difference (RRR = 2%; 95% CI -7% to 10%). Omeprazole and lansoprazole-containing triple therapies achieved similar eradication rates, but rabeprazole appeared superior to omeprazole (RRR = 8%; 95% CI 2% to 14%). The optimum clarithromycin dose in a PAC regimen was 500 mg twice daily (RRR = 11%; 95% CI = 3% to 18%), but 250mg twice daily in a PCM regimen (RRR = 2%; 95% CI -4% to 7%). Eradication rates were lower with a seven day regimen compared with fourteen (RRR = 12%; 95% CI 7% to 17%). Overall there was no difference between a PAC and a PCM regimen (RRR = 0%; 95% CI -3% to 3%).
CONCLUSIONS: PAC and PCM regimens are equally effective if used optimally, though PCM is cheaper. The eradication regimen and its duration should be tailored according to the clinical situation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845349     DOI: 10.1155/2003/714124

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  22 in total

1.  Eradication of H. pylori Infection: the Challenge is on if Standard Therapy Fails.

Authors:  Ulrich R M Bohr; Peter Malfertheiner
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 2.  Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management.

Authors:  M-Q Du; J C Atherton
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

Review 3.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

4.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

Review 5.  One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm.

Authors:  David Y Graham; Yoshio Yamaoka
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

6.  Update on Therapeutic Options for Helicobacter pylori-related Diseases.

Authors:  Francis Mégraud
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

Review 7.  Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.

Authors:  Javier Molina-Infante; Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

8.  Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.

Authors:  Rocco Maurizio Zagari; Gabriele Bianchi-Porro; Roberto Fiocca; Giovanni Gasbarrini; Enrico Roda; Franco Bazzoli
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

9.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

Review 10.  Gastroenterology in developing countries: issues and advances.

Authors:  Kate L Mandeville; Justus Krabshuis; Nimzing Gwamzhi Ladep; Chris J J Mulder; Eamonn M M Quigley; Shahid A Khan
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.